Why Teva Pharmaceutical Industries Limited (NYSE:TEVA) Is In News?


Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $68.770 on Teva Pharmaceutical Industries Limited (NYSE:TEVA) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $5.270 for the next fiscal and $N/A for underway quarter.

Valuation Estimates

Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) stands at 34.452.

Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Teva Pharmaceutical Industries , the PEG ratio for coming 3-5 years is 1.710.

Technical Analysis

The technical analysis highlights that Teva Pharmaceutical Industries current is trading $-1.672 points away or -3.140% from its 50-day moving average of $53.247. Further it is trading $-2.132 or -3.969% away its 200-day moving average of $53.707.

The 52-week high of Teva Pharmaceutical Industries Limited (NYSE:TEVA) was $66.550 while lowest point recorded in 52-week was $48.010. It implies if stock price makes a movement of over $-14.975, it will record a new 52-week high. In the case of +7.426% drop, it will touch a new 52-week low.

1 Chart Pattern Every Investor Should Know

This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...

Click Here to See This Now.

(Visited 32 times, 1 visits today)